黑色素通过EGFR酸化的特定结合和抑制抑制子宫内膜异位症的生长
Yiran Li1,2, Sze-Wan Hung1, Xu Zheng1
1Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.
Journal of pineal research
|December 23, 2024
概括
黑色素有效地通过向表皮生长因子受体 (EGFR) 来抑制子宫内膜异位症病变的生长. 这项研究揭示了黑激素.
科学领域:
- 妇科 妇科医生 妇科
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 子宫内膜异位症是一种慢性妇科疾病,其特点是子宫外的子宫内膜组织.
- 细胞增殖是子宫内膜异位症病理生理学的关键因素.
- 一种荷尔蒙 - - 黑色素 (melatonin) 已经显示出对子宫内膜异位症的治疗潜力,但它的点和机制尚不清楚.
研究的目的:
- 研究美拉在子宫内膜异位症中直接结合的标和分子机制.
- 在子宫内膜异位症的临床前模型中评估黑激素的治疗疗效.
主要方法:
- 建立一个药物-疾病蛋白-蛋白相互作用 (PPI) 网络.
- 鉴定表皮生长因子受体 (EGFR) 作为黑素结合标.
- 使用计算模拟和生物层干扰测量来确认结合亲和力.
- 在体外和体内分析黑素对EGFR酸化,PI3K-Akt通路和细胞循环调节器 (CCND1) 的影响.
主要成果:
- 黑色素治疗抑制了小鼠模型和人类细胞系中的子宫内膜病变生长.
- EGFR被确定为内膜异位症中黑激素的新型结合标.
- 黑色素降低了EGFR的酸化,并抑制了PI3K-Akt通路.
- 通过向下调节CyclinD1 (CCND1) 来诱导 Melatonin 诱导的细胞循环停止.
- 在体外和体内实验证实了已识别的目标和途径的作用.
结论:
- 黑色素通过向EGFR显示出对子宫内膜异位症的治疗潜力.
- 黑色素通过EGFR-PI3K-Akt-CCND1信号通路抑制子宫内膜异位症的进展.
- 黑色素是治疗子宫内膜异位症的一种有前途的新疗法.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Hormonal Regulation of the Menstrual Cycle
289
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
289
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


